170 related articles for article (PubMed ID: 16738849)
1. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.
Machlenkin A; Azriel-Rosenfeld R; Volovitz I; Vadai E; Lev A; Paz A; Goldberger O; Reiter Y; Tzehoval E; Benhar I; Eisenbach L
Cancer Immunol Immunother; 2007 Feb; 56(2):217-26. PubMed ID: 16738849
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
[TBL] [Abstract][Full Text] [Related]
3. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
4. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Johnson LE; McNeel DG
Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
[TBL] [Abstract][Full Text] [Related]
5. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
7. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
9. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
10. CD4 T-Cell-mediated immune response to prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel HLA-DRB1*1503-restricted T-cell epitope from human prostatic acid phosphatase.
Klyushnenkova EN; Alexander RB
Prostate; 2011 May; 71(6):561-6. PubMed ID: 20886538
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
12. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
13. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
14. An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma.
Spies E; Reichardt W; Alvarez G; Groettrup M; Ohlschläger P
Mol Ther; 2012 Mar; 20(3):555-64. PubMed ID: 22086231
[TBL] [Abstract][Full Text] [Related]
15. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
Cancer Immunol Immunother; 2013 Dec; 62(12):1831-40. PubMed ID: 24149465
[TBL] [Abstract][Full Text] [Related]
16. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
18. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects.
Francini G; Scardino A; Kosmatopoulos K; Lemonnier FA; Campoccia G; Sabatino M; Pozzessere D; Petrioli R; Lozzi L; Neri P; Fanetti G; Cusi MG; Correale P
J Immunol; 2002 Nov; 169(9):4840-9. PubMed ID: 12391194
[TBL] [Abstract][Full Text] [Related]
19. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
20. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
